All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
ASCO 2016 | Early Intensification of Rituximab Plus 2-Weekly CHOP Showed No Significant Improvement to CR or PFS in Patients with Stage II-IV DLBCL
This ASCO 2016 oral abstract presentation took place on Sunday June 5, 9:45am–12:45pm, during the ‘Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia’ session. This session was chaired by Pr Gilles Salles, Head of the Hematology Department in South Lyon hospitals, Lyon, France.
The abstract (#7504) was presented by Dr Pieternella J Lugtenburg of Erasmus MC, Rotterdam, Netherlands.
In patients with Diffuse Large B-Cell Lymphoma (DLBCL), the standard care option is R-CHOP. However, the optimal rituximab dose and schedule is yet to be determined. A randomized, phase III study (NTR number: 1014) was initiated to compare standard R-CHOP-14 and R-CHOP-14 with 4 additional rituximab administrations (375mg/m2 IV on day 8) during the initial 4 cycles.
It was hypothesized that better response rates (CR) will be achieved in the early intensification of rituximab plus 2-weekly CHOP arm (arm B) than the standard arm (arm A). The primary endpoint was metabolic complete remission rate after induction treatment.
Inclusion criteria for this study included: confirmed histologic diagnosis of DLBCL according to WHO classification, CD20+, Ann Arbor stages II–IV, and age range of 66–80 years. Patients in CR after induction treatment were randomized between observation and rituximab maintenance.
During this talk, the efficacy results of the first randomization were presented.
- Overall, 575 pts randomized: Arm A = 286 pts; Arm B = 289 pts; baseline patient and disease characteristics were well balanced
- Median age = 65 years (range, 18–80); ≥66 years = 50% pts; male = 52%
- High-intermediate or high aa-IPI score = 57%
- CR: Arm A = 84%; Arm B = 82% (OR, 0.83; 95% CI, 0.54–1.28; P = 0.40)
- Observed CR rates for pts ≤65 or >65 years old were identical
- Median follow-up = 49 months (maximum 90 months)
- 3-year PFS: Arm A = 74%; Arm B = 71%
- 5-year PFS: Arm A = 68%; Arm B = 61% (HR, 1.23; 95% CI, 0.92–1.63; P = 0.16)
- No significant improvement in PFS was found in subgroups by age (≤65 or >65 years) or gender
- OS: Arm A = 69%; Arm B = 92% (HR, 1.36; 95% CI, 0.99–1.86; P = 0.06)
Intensified compared to standard rituximab did not improve CR rate, OS or PFS. In addition, no benefit was observed in any of the clinical subgroups (age or gender). Intensification of rituximab resulted in more toxicity in patients aged between 66 and 80 years, in particular neutropenia during cycles 1–4, vs. standard rituximab. Pieternella Lugtenburg concluded the talk by stating that intensification of rituximab is of no benefit.
References